Cullinan Management, Inc.(CGEM)

Description: Cullinan Oncology, LLC, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Its lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. The company's preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell acute lymphoblastic leukemia; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. It has a collaboration agreement with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, LLC was founded in 2016 and is headquartered in Cambridge, Massachusetts.

---

Keywords: Medicine Cancer Biopharmaceutical Clinical Medicine Immunology Solid Tumors Immune System Antibodies Oncology Tumor Cancer Immunotherapy Cell Therapy Monoclonal Antibody Non Small Cell Lung Cancer Acute Myeloid Leukemia Treatment Of Acute Myeloid Leukemia Therapies For Cancer Oncology Therapies B Cell Acute Lymphoblastic Leukemia Preclinical Products

---

Home Page: www.cullinanoncology.com

CGEM Technical Analysis

One Main Street
Cambridge, MA 02142
United States
Phone: 617 410 4650

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)